Total Payments
$64,063
2024 Payments
$10,234
Companies
56
Transactions
461
Medicare Patients
44,515
Medicare Billing
$12.3M
Payment Breakdown by Category
Consulting$45,719 (71.4%)
Food & Beverage$7,674 (12.0%)
Other$6,656 (10.4%)
Travel$2,592 (4.0%)
Education$1,422 (2.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $45,719 | 29 | 71.4% |
| Food and Beverage | $7,674 | 391 | 12.0% |
| Honoraria | $4,931 | 6 | 7.7% |
| Travel and Lodging | $2,592 | 12 | 4.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,725 | 1 | 2.7% |
| Education | $1,422 | 22 | 2.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $18,460 | 29 | $0 (2023) |
| BeiGene USA, Inc. | $5,821 | 10 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $4,599 | 17 | $0 (2024) |
| Daiichi Sankyo Inc. | $4,208 | 147 | $0 (2024) |
| Acceleron Pharma, Inc. | $4,000 | 2 | $0 (2020) |
| CTI BioPharma Corp. | $3,450 | 2 | $0 (2023) |
| Lilly USA, LLC | $2,702 | 7 | $0 (2024) |
| PharmaEssentia USA Corporation | $2,306 | 2 | $0 (2023) |
| Heron Therapeutics, Inc. | $2,079 | 2 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,731 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,234 | 210 | BeiGene USA, Inc. ($2,734) |
| 2023 | $13,239 | 147 | PharmaEssentia USA Corporation ($2,306) |
| 2022 | $18,717 | 57 | Bayer HealthCare Pharmaceuticals Inc. ($10,800) |
| 2021 | $4,634 | 10 | Coherus Biosciences Inc. ($1,650) |
| 2020 | $4,225 | 7 | Acceleron Pharma, Inc. ($4,000) |
| 2019 | $7,196 | 17 | Bayer HealthCare Pharmaceuticals Inc. ($6,424) |
| 2018 | $5,788 | 11 | AstraZeneca Pharmaceuticals LP ($2,790) |
| 2017 | $29.83 | 2 | Alexion Pharmaceuticals, Inc. ($19.67) |
All Payment Transactions
461 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $10.37 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $32.02 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $8.81 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $3.92 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/13/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $1.32 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $34.10 | General |
| 12/12/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $6.05 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/11/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $24.33 | General |
| Category: Iron Deficiency Anemia | ||||||
| 12/09/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $15.09 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,522.50 | General |
| 12/05/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $23.35 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $19.33 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $7.65 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $15.30 | General |
| 12/02/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $8.33 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | VPRIV (Biological) | Food and Beverage | In-kind items and services | $19.14 | General |
| Category: GENETIC DISEASE | ||||||
| 11/25/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $10.07 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: Oncology | ||||||
| 11/20/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $18.93 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $0.65 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/19/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $22.31 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/18/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $9.90 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2024 | Lilly USA, LLC | VERZENIO (Drug) | Education | In-kind items and services | $155.18 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $39.83 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 101 | 11,043 | 359,865 | $15.7M | $3.1M |
| 2022 | 101 | 11,344 | 298,232 | $15.1M | $3.1M |
| 2021 | 99 | 10,495 | 313,989 | $14.5M | $2.7M |
| 2020 | 113 | 11,633 | 394,518 | $17.7M | $3.4M |
Total Patients
44,515
Total Services
1,366,604
Medicare Billing
$12.3M
Procedure Codes
414
All Medicare Procedures & Services
414 procedure records from CMS Medicare Utilization — Page 1 of 17
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 45 | 38,609 | $5.7M | $1.6M | 29.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 71 | 13,200 | $928,800 | $243,755 | 26.2% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 14 | 4,880 | $1.2M | $163,881 | 13.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 600 | 1,472 | $329,728 | $140,155 | 42.5% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 46 | 41,700 | $875,700 | $97,693 | 11.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 294 | 620 | $186,620 | $84,235 | 45.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 148 | 699 | $479,514 | $72,770 | 15.2% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 11 | 2,920 | $566,480 | $65,744 | 11.6% |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | Office | 2023 | 12 | 2,490 | $413,340 | $56,780 | 13.7% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 111 | 98,431 | $590,586 | $39,074 | 6.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 632 | 2,259 | $140,058 | $23,332 | 16.7% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 14 | 25,500 | $127,500 | $22,486 | 17.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 656 | 2,843 | $99,505 | $21,541 | 21.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 180 | 429 | $130,416 | $21,364 | 16.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 648 | 2,520 | $47,880 | $21,041 | 43.9% |
| 82306 | Vitamin d-3 level | Office | 2023 | 404 | 662 | $160,866 | $19,107 | 11.9% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 58 | 68 | $95,200 | $17,161 | 18.0% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 457 | 967 | $75,426 | $15,917 | 21.1% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 21 | 111 | $437,118 | $14,631 | 3.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 88 | 88 | $38,016 | $14,446 | 38.0% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 234 | 1,476 | $79,704 | $13,426 | 16.8% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 614 | 2,182 | $65,460 | $12,849 | 19.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 196 | 927 | $97,335 | $11,441 | 11.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 61 | 219 | $73,146 | $11,109 | 15.2% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 323 | 766 | $44,428 | $10,187 | 22.9% |
About Dr. Rupesh Parikh, MD
Dr. Rupesh Parikh, MD is a Hematology & Oncology healthcare provider based in Henderson, Nevada. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245249689.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rupesh Parikh, MD has received a total of $64,063 in payments from pharmaceutical and medical device companies, with $10,234 received in 2024. These payments were reported across 461 transactions from 56 companies. The most common payment nature is "Consulting Fee" ($45,719).
As a Medicare-enrolled provider, Parikh has provided services to 44,515 Medicare beneficiaries, totaling 1,366,604 services with total Medicare billing of $12.3M. Data is available for 4 years (2020–2023), covering 414 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Henderson, NV
- Active Since 08/05/2006
- Last Updated 03/21/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1245249689
Products in Payments
- Xofigo (Drug) $12,370
- Nubeqa (Drug) $5,114
- BRUKINSA (Drug) $4,971
- Reblozyl (Drug) $4,000
- Vonjo (Drug) $3,450
- CYRAMZA (Drug) $2,510
- BESREMI (Drug) $2,306
- SUSTOL (Drug) $2,079
- Lenvima (Drug) $1,638
- KRAZATI (Drug) $1,590
- CALQUENCE (Drug) $1,486
- TEVIMBRA (Drug) $1,375
- XPOVIO (Drug) $1,202
- Enhertu (Drug) $1,083
- Stivarga (Drug) $962.50
- TAGRISSO (Drug) $946.88
- IMFINZI (Drug) $930.00
- Onivyde (Drug) $750.00
- LUMAKRAS (Drug) $712.36
- IMFINZI (Biological) $630.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Henderson
Dr. Russell Gollard, M.d, M.D
Hematology & Oncology — Payments: $179,843
Hematology & Oncology $179,843
Dr. Anthony Nguyen, Md, MD
Hematology & Oncology — Payments: $173,344
Hematology & Oncology $173,344
Dr. Ramalingam Ratnasabapathy, Md, MD
Hematology & Oncology — Payments: $27,968
Hematology & Oncology $27,968
Stephani Christensen, M.d, M.D
Hematology & Oncology — Payments: $21,536
Hematology & Oncology $21,536
David Mack, M.d, M.D
Hematology & Oncology — Payments: $11,273
Hematology & Oncology $11,273
Nutan Parikh, M.d. Ltd Apc, M.D. LTD APC
Hematology & Oncology — Payments: $8,315
Hematology & Oncology $8,315